Pharmaron Beijing Co., Ltd.
300759
Rang in aandelen
#2354
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a... Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services. In addition, the company is involved in the provision of technology development, technology transfer, technical consultation, technical services, and technical training; import and export of goods and technologies. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
Aandeelprijs
$5.58
Marktkapitalisatie
$8.24B
Verandering (1 dag)
-3.77%
Verandering (1 jaar)
28.36%
Land
CN
Handel Pharmaron Beijing Co., Ltd. (300759)
Categorie
Healthcare
Winst voor Pharmaron Beijing Co., Ltd. (300759)
Winst in Jun 2026 TTM: $303.40M
Volgens de meest recente financiële verslagen van Pharmaron Beijing Co., Ltd. bedraagt de huidige winst van het bedrijf $303.40M. In 2024 behaalde het bedrijf een winst van $286.51M, een stijging ten opzichte van de winst van 2023, die $259.64M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Pharmaron Beijing Co., Ltd. van 2014 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2026 (TTM) | $303.40M | 10.98% |
| 2025 | $273.38M | -4.58% |
| 2024 | $286.51M | 10.35% |
| 2023 | $259.64M | 7.48% |
| 2022 | $241.58M | -19.65% |
| 2021 | $300.66M | 48.87% |
| 2020 | $201.96M | 122.33% |
| 2019 | $90.84M | 59.17% |
| 2018 | $57.07M | 33.32% |
| 2017 | $42.81M | 38.55% |
| 2016 | $30.90M | 129.26% |
| 2015 | $13.48M | 188.75% |
| 2014 | $4.67M | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| $5.27B | 1,638.58% |
US
|
|
| $-3.09B | -1,117.46% |
US
|
|
| $-4.02B | -1,423.72% |
AU
|
|
| $2.85B | 837.94% |
BE
|
|
| $1.95B | 542.93% |
NL
|
